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Abstract: The long non-coding RNA ANRIL, antisense to the CDKN2B locus, is transcribed from a
gene that encompasses multiple disease-associated polymorphisms. Despite the identification of
multiple isoforms of ANRIL, expression of certain transcripts has been found to be tissue-specific
and the characterisation of ANRIL transcripts remains incomplete. Several functions have been
associated with ANRIL. In our judgement, studies on ANRIL functionality are premature pending
a more complete appreciation of the profusion of isoforms. We found differential expression of
ANRIL exons, which indicates that multiple isoforms exist in melanoma cells. In addition to linear
isoforms, we identified circular forms of ANRIL (circANRIL). Further characterisation of circANRIL
in two patient-derived metastatic melanoma cell lines (NZM7 and NZM37) revealed the existence
of a rich assortment of circular isoforms. Moreover, in the two melanoma cell lines investigated,
the complements of circANRIL isoforms were almost completely different. Novel exons were also
discovered. We also found the family of linear ANRIL was enriched in the nucleus, whilst the circular
isoforms were enriched in the cytoplasm and they differed markedly in stability. With respect to the
variable processing of circANRIL species, bioinformatic analysis indicated that intronic Arthrobacter
luteus (Alu) restriction endonuclease inverted repeats and exon skipping were not involved in
selection of back-spliced exon junctions. Based on our findings, we hypothesise that “ANRIL” has
wholly distinct dual sets of functions in melanoma. This reveals the dynamic nature of the locus and
constitutes a basis for investigating the functions of ANRIL in melanoma.
Keywords: melanoma; long noncoding RNA; ANRIL; circular RNA; isoforms; CDKN2A/B
1. Introduction
ANRIL (antisense non-coding RNA in the INK4A locus) is a long non-coding RNA (lncRNA)
that was originally identified in familial melanoma patients with a large germline deletion in the
CDKN2A/B (also known as INK4B-ARF-INK4A) gene cluster and is reported to be deregulated in
several malignancies such as gastric, breast, lung and bladder cancer [1–5]. This locus has further been
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identified as a hotspot for disease-associated polymorphisms and it has been consistently associated
with cardiovascular disease, several cancers, diabetes, glaucoma and other conditions [6].
The most commonly accepted function of ANRIL is that it mediates repression of the CDKN2A/B
locus, by association with polycomb repressor complexes (PRC1 and PRC2) [7]. However, divergent
reports have suggested both concordant and discordant expression of CDKN2A or CDKN2B and
ANRIL, again in different tissues and cell types [1,7–12]. Additionally, repression of CDKN2A/B by
ANRIL via PRC1 and PRC2 is under re-evaluation due to the promiscuous nature of binding of the
PRC components to RNA molecules [13].
The existence of multiple linear and circular ANRIL (circANRIL) isoforms has been reported by
several groups [9,10,14]. Recently, circANRIL was found to be associated with ribosome biogenesis and
nucleolar stress [15]. Despite the numerous splicing variants that have been described, characterisation
of the isoforms in different cell lines and tissues is still incomplete, and a more complete inventory of
these should be acquired (providing data on length, exon inclusion and potential secondary structure)
before functional studies are undertaken. Characterisation is crucial as some of these splice variants
have been reported to be cell- or tissue-specific, suggesting that they are of physiological relevance
and that they mediate a variety of effects.
In some contexts, trans-regulation was found to be dependent on Alu motifs, which marked the
promoters of ANRIL target genes and which were mirrored in ANRIL transcripts [14]. ANRIL transcripts
containing the Alu repeats were predicted to form a stem-loop structure, suggesting RNA-chromatin
interactions as potential effector mechanisms [14].
Considering this, we set out to characterise the isoforms of ANRIL present in melanoma cells.
We chose this cell type because of the importance of the chromosome 9p21 locus including CDKN2A/B
and ANRIL in familial and sporadic melanoma, and the availability of a large panel of New Zealand
melanoma (NZM)-derived cell lines. We chose two cell lines, one producing CDKN2A (p16) protein
and one not, which were being characterised as part of a separate study, but were selected for this study
to ascertain whether their complement of ANRIL isoforms evinced the same specificity of processing,
and whether their production conformed to patterns described by others. We found that these
melanoma lines expressed a profusion of both linear and circANRIL isoform variants. Characterisation
of the large number of circular isoforms, which appeared to be largely different in the two cell lines,
further revealed the true complexity of this locus. We observed variability in the localisation pattern of
these isoforms with linear ANRIL enriched in the nucleus and circANRIL enriched in the cytoplasm.
Additionally, we found that the processing of circANRIL did not fit in with the published models of
circRNA biogenesis that invoke either duplex formation of inverted Alu repeats located in long introns
that flank exons, or “exon skipping” [16].
2. Results
2.1. Differential Expression of ANRIL Exons in Melanoma Lines
To determine general expression levels, it would be ideal to consider the total length of the
ANRIL transcript. However, due to the length of the ANRIL transcript, quantitative PCR (qPCR) was
performed using five primer sets (Figure 1A) that covered several exons along the full length of the
ANRIL transcript (Figure 1B,C and Figure S1A–C). Primer sets were created targeting the 5′ exon 1,
the middle exons (exon 5-6 and exon 6-7) and the last 3′ exons that distinguish between the short
and long isoforms (Figure 1A). To differentiate between exon 13 in the transcript with 19 exons and
the last exon of the short transcript with 13 exons, we have referred to them as exon 13a and exon
13b, respectively. Differential expression of exons was observed in each of five melanoma lines which
were selected from our panel at random (Figure 1B,C and Figure S1A–C). Proximal exons (exon 1
and exon 5-6) were highly expressed relative to the distal exons (exon 13b and exon 19) (Figure 1B,C
and Figure S1A–C). An elevated expression of exon 13b in comparison with exon 19 (last exon of the
long isoform) indicates that the shorter isoform is more abundant than the longer isoform of ANRIL.
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Higher levels of expression of exons 5-7 may reflect the contribution of these exons to shorter isoforms
(Figure 1B,C and Figure S1A–C).Int. J. Mol. Sci. 2017, 18, 1378  3 of 18 
 
 
Figure 1. Differential expression of ANRIL exons/isoforms in melanoma cell lines. (A) Schematic of 
two isoforms of ANRIL. The arrows indicate primer sets used to detect different exons and isoforms 
of ANRIL. F and R represent forward and reverse for each primer set, respectively. Primer set 2F/2R 
is targeted to the first exon, and 3F/3R along with 4F/4R target middle exons which are common in all 
isoforms. Primer sets 5F/5R and 6F/6R target the last exons of the short (exon 13b) and long (exon 19) 
isoform of ANRIL, respectively, and were used to distinguish between them; (B,C) Differential 
expression of ANRIL exons in NZM7 and NZM37 cell lines by qPCR using primer sets described in 
(A), which indicate low expression levels for the distal exons (exons 13b and exon 19) as compared to 
the proximal exons (exon 1, exon 5-6); n = 2; (D) Mean expression levels of each exon of ANRIL, from 
TCGA RNA-seqV2-2013 data; n = 255. 
Differential expression of exons indicates that multiple ANRIL isoform variants exist in these 
melanoma lines. We also determined expression levels of each exon of ANRIL for all the skin 
cutaneous melanoma (SKCM) cases in TCGA database (n = 255; Figure 1D). This data set also 
revealed differential expression of all 19 exons of ANRIL transcripts, with exon 8 having the lowest 
expression (Figure 1D), emphasising the presence of multiple isoform variants in ex vivo tumour 
specimens. 
Expression levels of exon 1 and exons 5-6 in our set of melanoma cell lines (Figures 1B,C and 
S1A–C) were consistent with those of TCGA data set (Figure 1D). However, combined expression of 
exons 6-7 and distal exon 19 in the melanoma lines was low compared to the TCGA data set (Figures 
1B–D and S1A–C). 
2.2. Expression and Stability of circANRIL Relative to Linear ANRIL 
Burd et al. [10] reported the existence of circANRIL with an exon 14-5 head-to-tail junction as the 
predominant form in immortalized fibroblast cell lines. We set out to ascertain whether this novel 
isoform existed in our panel of melanoma lines. A preliminary PCR study was done using the NZM7 
cell line to detect the presence of circANRIL. Two primer sets were used to detect the exon 14-5 
Figure 1. Differential expression of ANRIL exons/isoforms in melanoma cell lines. (A) Schematic of
two isoforms of ANRIL. The arrows indicate primer sets used to detect different exons and isoforms of
ANRIL. F and R represent forward and reverse for each primer set, respectively. Primer set 2F/2R is
targeted to the first exon, and 3F/3R along with 4F/4R target middle exons which are common in all
isoforms. Primer sets 5F/5R an 6F 6R target the last exons of the short (exon 13b) and long (exon
19) isofor of A ctively, and were used to distinguish between them; (B,C) Differential
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(A), which indicate low expression levels for the istal exons (exons 13b and exon 19) as compared to
the proximal exons (exon 1, exon 5-6); n = 2; (D) ean expression levels of each exon of ANRIL, from
TCGA RNA-seqV2-2013 data; n = 255.
Differential expression of exons indicates that multiple ANRIL is form variants exist in these
melanoma lines. We also determined xpression levels of ach exon of ANRIL for all the skin cutaneous
melanom (SKCM) cases in TCGA databas (n = 255; Figure 1D). This data set also revealed diff rential
expression of all 19 exons of ANRIL transcripts, with exon 8 having the lowest expression (Figure 1D),
emphasising the presence of multiple isoform variants in ex vivo tumour specimens.
Expression levels of exon 1 and exons 5-6 in our set of melanoma cell lines (Figure 1B,C and
Figure S1A–C) were consistent with those of TCGA data set (Figure 1D). However, combined expression
of exons 6-7 and distal exon 19 in the melanoma lines was low compared to the TCGA data set
(Figure 1B–D and Figure S1A–C).
2.2. Expression and Stability of circANRIL Relative to Linear ANRIL
Bur et al. [10] reported the existence of cir ANRIL with an exon 14-5 head-to-tail juncti n as the
predominant form i immortalized fibrob ast cell lines. We set out to ascertain whet r this novel
isoform existed in our panel of melanoma lines. A preli inary PCR study was done using the NZM7
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cell line to detect the presence of circANRIL. Two primer sets were used to detect the exon 14-5 junction
(Figure 2A and Figure S2A). We initially used primers as reported by Burd et al. [10] and subsequently
primers designed in-house to detect the same junction (Table S1). Total RNA from NZM7 cells was
reverse transcribed using random hexamers, as circANRIL does not have a polyadenylated tail. PCR
products were detected using both primer sets and sequencing of the PCR product confirmed the
presence of the exon 14-5 junction, along with an exon 14-4 junction (Figure 2A and Figure S2A–D).
Following this, qPCR was performed to detect expression levels of circANRIL in 14 melanoma cell lines
using the in-house designed exon 14-5 junction primer set (Figure 2B). Only one peak was observed
in the dissociation curve (Figure S2B), followed by visualization of the qPCR product on agarose gel,
which further confirmed detection of only the exon 14-5 junction (Figure S2C). Except for NZM3 cells
(a negative control with a deleted locus) and NZM44 and NZM55 cells, circANRIL was expressed in all
the melanoma lines tested (Figure 2B).
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Figure 2. Expression and stability of circANRIL isoform in melanoma cell lines. (A) Exon 14-5 
junction indicative of circANRIL isoform confirmed using Sanger sequencing; (B) Expression levels of 
the exon 14-5 junction indicative of circANRIL isoform relative to expression levels of 18S and 28S in 
16 melanoma cell lines; (C) Comparison of expression levels of circular and linear ANRIL (p = 0.143, r2 
= 0.148) using scatter plot and spearman correlation; (D,E) The stability of circANRIL represented by 
the exon 14-5 junction (using the in-house designed primer set) in comparison to that of linear ANRIL 
represented by expression of exon 1 after actinomycin D treatment of melanoma cells; (D,E) 
represent NZM7 and NZM37 cells, respectively. Expression was normalized to GAPDH for exon 1 
and exon 14-5 junction for each time point, and fold change calculated against time 0. Linear 
regression analysis was done for both exon 1 and exon 14-5. Error bars indicate SEM and n = 3. 
Figure 2. Expression and stability of circANRIL isoform in melanoma cell lines. (A) Exon 14-5 junction
indicative of circANRIL isoform confirmed using Sanger sequencing; (B) Expression levels of the
exon 14-5 junction indicative of circANRIL isoform relative to expression levels of 18S and 28S in 16
melano a cell lines; (C) Comparison of expression levels of circular and linear ANRIL (p = 0.143,
r2 = 0.148) using scatter plot an n co relation; (D,E) The stability of circANRIL represented by
the exon 14-5 junction (using the in-house designe er set) in comparison to hat of linear ANRIL
represented by expression of exon 1 after actinomycin D treatment of melanoma cells; (D,E) represent
NZM7 and NZM37 cells, respectively. Expression was normalized to GAPDH for exon 1 and exon 14-5
junction for each time point, and fold change calculated against time 0. Linear regression analysis was
done for both exon 1 and exon 14-5. Error bars indicate SEM and n = 3.
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Expression levels of circular (containing exon 14-5 junction) and linear ANRIL isoform variants
for 16 samples were analyzed using SigmaPlot V13.0 (SYSTAT Software, San Jose, CA, USA).
Spearman correlation was also determined for each pair of samples. No correlation was found
for the expression of linear and circANRIL variants (Figure 2C, p > 0.05).
The stability of circular and linear ANRIL isoforms was also determined after actinomycin D
treatment of melanoma cells (Figure 2D,E). Linear regression analysis was done to determine stability
of circANRIL and linear ANRIL. CircANRIL (p = 0.063) was found to be more stable than its linear
counterpart (p = 0.0156) in case of NZM7 (Figure 2D). Even though p value for linear exon 1 in case
of NZM37 was not found to be significant, a similar trend as NZM7 was observed with circANRIL
(p = 0.66) comparatively more stable than linear ANRIL (p = 0.327).
2.3. Characterisation of circANRIL Isoforms
Further characterization of circANRIL isoforms was undertaken by employing a unbiased,
systematic approach using outward-facing primers against exons 2, 4, 6, 7, 8, 10, 12, 19, 14, 16,
17 and 18 (Table 1 and Figure S2E), of which primers targeting exons 4, 6 and 16 were as reported by
Burd et al. [10]. Outward-facing primers could not be designed against exons 3, 5, 9, 11, 13 and 15
because these exons were of insufficient length. The priming strategy using outward-facing primers
specific for exons 2, 4, 6, 7, 8, 14 and 16 identified a more comprehensive collection of circANRIL
isoforms with various exon combinations and non-canonical, head-to-tail back-spliced junctions
(Table 1 and Figure S2E).
Table 1. Isoforms of circANRIL identified in this study using outward-facing primers against different
exons. Isoforms shown in bold indicate isoforms common to NZM7 and NZM37 cells. The back-spliced
junction for each isoform is indicated in brackets beside the isoform sequence. N1 and N2 denote
novel exons.
Target Exons for Outward Primers NZM7 CircANRIL Isoforms NZM37 CircANRIL Isoforms
Exon 2 2-5-6-2
Exon 4
4-5-6-9-10-4 (10-4)
4-5-6-7-10-12-4 (12-4)
4-5-6-7-4 (7-4)
4-5-6-13-14-4 (14-4)
4-5-6-10-13-14-4 (14-4)
4-5-13-14-4 (14-4)
4-5-6-12-13-14-4 (14-4)
4-5-6-13-14-4 (14-4)
4-5-6-4 (6-4)
4-5-6-10-11-12-4 (12-4)
4-5-6-7-4 (7-4)
4-5-6-7-13-14-4 (14-4)
Exon 6
6-4-5-6 (6-4)
6-14-5-6 (14-5)
6-7-9-10-6 (10-6)
6-9-10-5-6 (10-5)
6-10-2-5-6 (10-2)
6-9-6 (9-6)
6-4(N1)-4(N2)-5-6 (6-4N1)
6-4(N2)-4-5-6 (6-4N2)
6-7-5-6 (7-5)
6-7-6 (7-6)
6-14-6 (14-6)
6-10-5-6 (10-5)
6-7-10-4-5-6 (10-4)
6-7-10-5-6 (10-5)
6-14-5-6 (14-5)
6-7-9-10-5-6 (10-5)
6-4-5-6 (6-4)
Exon 7 7-5-6-7 (7-5)
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Table 1. Cont.
Target Exons for Outward Primers NZM7 CircANRIL Isoforms NZM37 CircANRIL Isoforms
Exon 8
8-5-6-8 (8-5)
8-5-6-7-8 (8-5)
8-9-10-5-6-7-8 (10-5)
8-13-14-5-6-8 (14-5)
8-10-13-14-5-6-8 (14-5)
Exon 14
14-4-5-6-7-14 (14-4)
14-4-5-6-14 (14-4)
14-5-6-13N1-13-14 (14-5)
14-5-6-7-13-14 (14-5)
14-16-13N1-13-14 (16-13N1)
14-5-6-14 (14-5)
14-5-6-13-14 (14-5)
14-4-5-6-7-14 (14-4)
14-5-6-7-13-14 (14-5)
14-4-5-6-7-9-14 (14-4)
14-4-5-6-7-13-14 (14-4)
14-5-6-7-10-13-14 (14-5)
14-5-6-7-9-10-13-14 (14-5)
14-4-5-6-7-10-13-14 (14-4)
14-5-6-7-10-12-13-14 (14-5)
Exon 16
16-15-16 (16-15)
16-5-6-7-13-14-15-16 (16-5)
16-6-7-13-14-15-16 (16-4)
14-15-16-19-5-6-10-13-14 (19-5)
16-5-6-7-13-14-15-16 (16-5)
Outward facing primers targeted against exons 2, 4, 6, 8, 14 and 16.
Two melanoma cell lines, NZM7 and NZM37, were selected for circANRIL characterization.
Transcripts from the NZM7 and NZM37 cell lines were analysed to detect and compare possible
variations in the circANRIL isoforms present. Multiple isoforms of circANRIL were observed (Table 1)
with various exon combinations and multiple junction variants in these two cell lines. Despite several
attempts, we could not detect circANRIL isoforms using outward-facing primers against exons 10, 12,
17 and 18 in either cell line. However, isoforms of circANRIL using outward-facing primers against
exons 8, 14 and 16 could be detected only in NZM7 and not in NZM37 cells, and the diversity of
circANRIL species was greater for NZM7 than NZM37 cells. Interestingly, except for four circANRIL
species (4-5-6-7-4 (7-4), 6-4-5-6 (6-4), 6-14-5-6 (14-5) and 14-4-5-6-7-14 (14-4), Table 1), the sets of circular
isoforms were different in the two cell lines. Comparison of back-spliced exon junctions between
NZM7 and NZM37, along with published back-spliced junctions found in the case of established cell
lines by Burd et al. [10] (Figure S3A), revealed some non-canonical back-spliced junctions that were
common to all the samples (exon 14-5, 7-4, 10-5 and 14-4). However, the diversity of back-spliced
junctions was greater with NZM7 as compared to NZM37 cells. In addition, some novel exons were
found, but only in NZM7 cells. Of all the isoforms detected in both cell lines, exons 4, 5 and 6 were
most abundantly found in almost all the circANRIL variants. We found new exons upstream of exon 4,
designated E4 (1) and E4 (2), that have not been reported previously (Figure S3B) and a novel splice
variant of exon 8 (with a 1400–1705 nucleotide base region deletion, Figure S3C). All of the novel exons
reported contained canonical splice sites.
2.4. Non-Canonical Back-Splicing of ANRIL
Published work describing circRNA in fibroblasts [16] has shown that back-spliced junctions are
formed due to the presence of inverted repeat elements present in the long flanking introns. In view
of the diverse circANRIL species and back-spliced exon junctions found in the melanoma cells, we
sought to investigate conditions which facilitate the formation of back-spliced junctions of circANRIL
in melanoma cells.
We examined the length of exons and introns from publicly available data for circRNA (Available
on: http://circbase.org). Analysis confirmed the length of exons and introns in circular and linear RNA
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to be similar (Figure S4A,B), and the number of Alu elements increased with the length of the introns
(Figure S4C,D). When we compared these data to circANRIL isoforms from both of our examined
melanoma cell lines, we noted that the pairing of inverted Alu elements and the length of introns
were not the only determining factors causing circularization of ANRIL. Alu repetitive sequences were
present in introns 1, 5, 6, 7, 11, 12 and 14 of ANRIL (Figure 3A). Introns 5, 6, and 7 contained 1, 3, and 2
Alu elements, respectively. These introns were found to be present in pre-spliced RNA in 34, 31 and
31, respectively, of the 37 circANRIL isoforms found in melanoma cell lines (Figure 3B and Table 1).
Among those, we found 6, 2 and 1 junctions that involved introns 5, 6 and 7, respectively. Introns 1
and 12 are the longest introns containing 7 and 10 Alu elements respectively (Figure 3A,B). The only
back-spliced events including these introns were observed in circANRIL containing junction 10-2 and
4-12, respectively, while intron 4, which is a short intron with no Alu elements, was present in most
junctions (5-7, 5-8, 5-10, 5-14, and 5-16).
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(A) Schematic showing Alu elements (indicated in red) in introns of ANRIL; (B) Graph showing length
of introns and the probability of introns to be included in the pre-processed circANRIL isoforms.
The length a d number of introns included i pre-process d circANRILs are scaled by dividing them by
their maximum o unify the with the [0, 1] range; (C) Abundance f xons in the circANRIL species
identified in melano a cell lines. Relative abundance for each exon is normalise against the exon
with maximum abundance for each cell line.
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The exons of ANRIL were also analyzed for the presence of Alu elements but as with published
reports [16], Alu elements were found only in exons 7 and 12, which contain one Alu element each.
These exons are not highly represented, nor do they feature frequently in circANRIL junctions in these
cells (Figure 3C and Table 1).
Analysis was also done to predict possible back-splicing events which may be attributed to the
presence of inverted Alu elements present in introns of ANRIL (Figure S5C). Inspection showed that
several intron pairs with reverse complementary Alu repeat sequences were found for introns 14-1, 12-1,
11-1, 11-6, 11-7, 6-1, 6-7, 7-5 and 5-1, which could potentially lead to back-splicing events between exons
14-2, 12-2, 11-2, 11-7, 11-8, 6-2, 7, 7-6 and 5-2, respectively (Figure S5C and Table S2). The validated
back-spliced junctions found in circANRIL species in the NZM cell lines (Table 1) confirmed only exon
6-2 and 7-6 back-spliced junctions. Those junctions could be formed due to presence of inverted repeat
sequences present in intron pairs 6-1 and 7-1 respectively (Table S3).
The possibility of an “exon skipping” mechanism that causes lariat formation leading to formation
of circRNAs has been proposed. Here, we examined this possibility for circANRIL. A series of exons
from ANRIL were extracted that were perhaps skipped based on “skipped” exon events identified
in RefSeq database (Table 2). However, none of these completely matched circANRIL variants found
in this study (Table 1), therefore we excluded the involvement of an exon skipping mechanism in
circANRIL formation.
Table 2. Exon junctions representing exon skipping events and the circANRIL isoforms such events
may have generated.
Exon–Intron Junction Potential CircANRIL
CDKN2B-AS1;SE:chr9:22029593-22032673:22032985-22046316:+ 3
CDKN2B-AS1;SE:chr9:22049227-22056251:22056386-22077678:+ 7, 8, 9, 10, 11, 12
CDKN2B-AS1;SE:chr9:22049227-22056251:22056386-22112319:+
CDKN2B-AS1;SE:chr9:22049227-22097257:22097363-22112319:+ 7, 8, 9, 10, 11, 12, 13, 14
CDKN2B-AS1;SE:chr9:22049227-22056251:22056386-22120199:+ 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
CDKN2B-AS1;SE:chr9:22049227-22120199:22120409-22120503:+ 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
CDKN2B-AS1;SE:chr9:22056386-22058358:22059053-22061952:+ 8
CDKN2B-AS1;SE:chr9:22056386-22061952:22062025-22063943:+ 8, 9
CDKN2B-AS1;SE:chr9:22056386-22063943:22064017-22077678:+ 8, 9, 10, 11, 12
CDKN2B-AS1;SE:chr9:22064017-22065661:22065756-22066234:+ 11
CDKN2B-AS1;SE:chr9:22064017-22066234:22066352-22077678:+ 11, 12
CDKN2B-AS1;SE:chr9:22112394-22113665:22113798-22118643:+ 16
2.5. Subcellular Localisation of Linear and Circular Isoforms of ANRIL Transcript
We sought to ascertain whether the diversity of linear and circANRIL isoforms was reflected in
patterns of subcellular localisation. Cell extracts were separated into nuclear and cytoplasmic fractions.
NEAT1, a nuclear RNA, and GAPDH were used as control transcripts to monitor the purity of the
fractions (Figure 4A and Figure S6A). We performed quantitative RT-PCR for different exons of ANRIL
(exon 1, exons 5-6, exons 6-7 and the last exons of both the short and long isoforms) in seven cell lines
(NZM6, NZM7, NZM37, NZM40, NZM48, NZM 55 and NZM87) (Figure 4B,C and Figure S6B–F).
The results confirmed enrichment of linear ANRIL in the nucleus.
Subcellular localization of circANRIL was also considered in the same set of melanoma lines.
Quantitative RT-PCR was performed using the primer set targeted towards the exon 14-5 junction.
Unlike linear ANRIL isoforms, most circANRIL transcripts localised to the cytoplasm as compared to
the nucleus for almost all cell lines (Figure 4D,E and Figure S7A–E).
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Figure 4. Sub-cellular localisation of circular and linear ANRIL transcripts in melanoma cell lines: (A) 
The purity of the cell fractions was checked by reverse transcription PCR (RT-PCR) using NEAT1 
(nuclear marker) and GAPDH in NZM7 and NZM37 cell extracts fractionated into nuclear and 
cytoplasmic fractions; (B,C) Linear ANRIL exons localised in the nucleus for NZM7 (B) and NZM37 
cells (C), as detected by qPCR and the same primer sets as described previously (Figure 1A). The fold 
change relative to whole cell extracts is shown; (D,E) Localisation of circANRIL in fractionated cells 
using the exon 14-5 junction primer set. The fold change relative to whole cells is shown in NZM7 (D) 
and NZM37 (E) cells. Expression levels for all the targets in cytoplasmic and nuclear fractions were 
normalized to the relevant housekeeping gene and compared to expression levels in whole 
(unfractionated) cells. Error bars represent SEM (n = 2). 
3. Discussion 
We set out to characterise isoforms of ANRIL in melanoma cells and have shown that various 
exons of ANRIL are differentially expressed, and that multiple isoforms of circANRIL exist. 
Characterisation of circANRIL in these cells revealed the presence of an assortment of circular 
isoforms with varying lengths, exon-exon junctions and exon combinations. On further analysis, we 
found that formation of non-canonical back-spliced junctions was not mainly determined by Alu 
elements present in introns. We also observed that linear and circANRIL isoforms differ in their 
Figure 4. Sub-cellular localisation of circular and linear ANRIL transcripts in melanoma cell lines:
(A) The purity of the cell fractions was checked by reverse transcription PCR (RT-PCR) using NEAT1
(nuclear marker) and GAPDH in NZM7 and NZM37 cell extracts fractionated into nuclear and
cytoplasmic fractions; (B,C) Linear ANRIL exons localised in the nucleus for NZM7 (B) and NZM37
cells (C), as detected by qPCR and the same primer sets as described previously (Figure 1A). The fold
change relative to whole cell extracts is shown; (D,E) Localisation of circANRIL in fractionated cells
using the exon 14-5 junction primer set. The fold change relative to whole cells is shown in NZM7
(D) and NZM37 (E) cells. Expression levels for all the targets in cytoplasmic and nuclear fractions
were normalized to the relevant housekeeping gene and compared to expression levels in whole
(unfractionated) cells. Error bars represent SEM (n = 2).
3. Discu sion
We set t t c aracterise isoforms of ANRIL in melanoma cells and have shown that various exons
of ANRIL are differentially expressed, and that multiple isoforms of circANRIL exist. Characterisation
of circANRIL i these ells revealed th presence of an assortment of circular is forms with varying
lengths, exon-exon junctions and exon combinations. On further analysis, we found that formation of
no -canonical back-spliced junctions was not mainly determined by Alu elements present in introns.
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We also observed that linear and circANRIL isoforms differ in their subcellular localisation, with linear
isoforms enriched in the nucleus and circANRIL enriched in the cytoplasm.
3.1. Existence of Multiple Isoforms of ANRIL—Linear and Circular
Next generation sequencing (RNA-seq) has revealed differences in the abundance of ANRIL
exons, with low expression of the central exons and high expression of the proximal and distal exons.
In addition to this, of the characterised linear isoforms of ANRIL, transcripts with proximal exons
1-7 and distal exons 13-19 were found to be most abundant and exons from 8 to 12 were found to be
skipped in the majority of mature transcripts [9,10,14].
The existence of multiple ANRIL species was evident through qPCR and RNA-seq data in the
panel of melanoma cell lines tested here and in melanoma samples in TCGA database respectively
(Figure 1B–D and Figure S1A–C). Expression levels of exons 1, 5 and 6 in our panel of melanoma cell
lines (Figure 1B,C and Figure S1A–C) were consistent with that of TCGA data (Figure 1D). However,
combined expression of exon 6-7 and distal exons 19 in melanoma cells was low as compared to TCGA
data (Figure 1B–D and Figure S1A–C). The discrepant expression levels may reflect the homogeneity of
melanoma cells as cultured lines as opposed to the heterogeneity of cell populations present in tumours
(TCGA), or a cell culture as opposed to in vivo tumour environment. Genomic deletions leading to
fusion of 5′-MTAP and 3′-ANRIL sequences have been described in melanomas [17]. The relatively
higher abundance of 3′-ANRIL sequences in TCGA samples might reflect a higher frequency of
melanomas with such deletions and thus divergent aetiologies.
Study of the expression levels of this locus is complex, as certain SNPs are reported to influence
the expression of ANRIL either in cis or trans mode [11]. The diversity of transcript variants reported
in both diseased and normal tissues [9,10,14], along with our data, requires that the effects of these
SNPs on transcript generation should be investigated.
Burd et al. [10] first reported the existence of a circANRIL isoform. Since our initial results
indicated the presence of multiple isoforms in melanoma, we investigated whether circANRIL is
present in our melanoma cells. CircANRIL was found to be present in most melanoma cell lines
(Figure 2B). However, the expression levels of transcripts with the exon 14-5 junction varied between
cell lines (Figure 2B). The circular isoform also seemed to be more abundantly expressed than the
linear isoforms. This could be due to the more stable nature of circANRIL (Figure 2D,E) as it is not
subject to the action of exonucleases due to the absence of free ends [18]. The expression levels of linear
and circANRIL isoforms were not significantly correlated (Figure 2C) indicating that the production of
circANRIL and linear ANRIL transcripts are independent of one another. This suggests the hypothesis
that linear and circular conformations are generated by independently regulated processing pathways.
3.2. Diversity of CircANRIL Species in Melanoma
We characterised circANRIL isoforms in two melanoma cell lines, NZM7 and NZM37, based on
their comparable expression levels of exon 14-5 junction-containing circANRIL species (Figure 2B and
Table 1). A wide diversity of circANRIL isoforms with different exon combinations, and indeed novel
exons, was identified in NZM7 and NZM37 cells. However, it is striking that these two cell lines had
almost wholly non-overlapping sets of circRNA species. Except for four circANRIL isoforms, no other
variants of the identified circANRIL transcripts were found to be common to both NZM7 and NZM37
cells, suggesting that the forms of circANRIL generated were produced in differentially regulated
contexts in the two cell lines (Table 1) and that they represent functional moieties rather than merely
transcriptional noise.
As with previous reports [14], we identified exons 4, 5 and 6 as the most frequently included
exons of all the circANRIL transcripts. Exons 10, 13 and 14 on the other hand were found less frequently.
CircANRIL isoforms containing exon 8 were found only in NZM7 and not in NZM37 cells. However,
full-length exon 8 was not identified in circANRIL (Figure S3C), but only a truncated form possessing a
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1400–1705 base region deletion, suggesting that longer exons are excluded from multi-exon circular
RNAs as shown (Figure 3C and Figure S5B).
Next-generation RNA-seq of HeLa cell transcriptomes revealed that the middle exons 4-12 of
linANRIL with 19 exons were least expressed compared to the proximal and distal exons [10]. However,
analysis of TCGA data for the SKCM cases revealed the expression of certain middle exons (exon
numbers 5, 6, 7, 10, 13, and 14) to be quite abundant. Other exons (8, 9 11 and 12) were poorly
represented. These findings are broadly consistent with the expression of the middle exons of ANRIL
in the panel of melanoma cell lines tested here (Figure 1B–D). This indicates tissue specific expression
of ANRIL and possible variation in isoform expression. In addition, the middle exons are found to
be abundant in circANRIL species identified in NZM7 and NZM37 cells. The diversity of circANRIL
transcripts identified might be taken to suggest that circANRIL is a mere by-product of an alternative
splicing mechanism via “exon skipping” [16,19]. However, the phenomenon of exon skipping was
analysed, and was shown not to be the cause for production of circANRIL species found in our
melanoma cells (Table 2).
Diverse populations of circANRIL could also arise due to the presence of SNPs in the melanoma
cell lines investigated, as SNPs associated with diseases including coronary artery disease (CAD),
diabetes, and cancers are highly associated with ANRIL expression and splicing [11]. The presence of
possible SNPs in melanoma cell lines therefore needs to be further investigated.
3.3. Back-Spliced Junctions in CircANRIL Species: Not Mediated by Intronic Alu Repeats
Identification of isoforms is critical as the function of ANRIL may vary with the type of transcript
variant expressed in each cell or tissue type, and hence secondary structure. Following this, further
characterisation of various isoforms of circANRIL using outward primers revealed several novel
isoforms, junctions, exons and splice variants of exons when compared to the previous study [10]
(Table 1). We found certain exons such as exon 5 and 6 present in almost all isoforms of circANRIL.
Previous studies have also confirmed the presence of exons 5 and 6, and junction 14-5 as the
predominant exons and junction, respectively. However, the diversity of isoforms is very variable in
different tissues examined so far [10,15] suggesting that circANRIL manifests a marked tissue specificity.
Jeck et al. proposed two models for biogenesis of circRNA [16,19]. The first model suggested
non-canonical back-splicing of exons was due to genomic structure of long exons flanked by long
introns harbouring inverted repeat elements. This preference to contain flanking Alu repeats was
observed for both single- as well as multiple-exon circRNAs. The second model proposed that an
alternative splicing mechanism “exon skipping” caused formation of circRNAs [16,19]. Therefore,
further analysis for the presence of Alu repeat elements was done using published databases and
circANRIL variants to investigate a possible role of these features in the circANRIL species identified in
our melanoma cells.
Analysis of introns in unprocessed transcripts revealed Alu repeats to be present in introns 1, 5,
6, 7, 11, 12 and 14 (Figure 3A), of which several pairs of introns, e.g., 1-6, 5-7 1-12 etc. (Figure S5C)
featured paired Alu elements, with sequences in reverse orientation. Back-splicing due to the presence
of inverted repeat-containing introns could therefore be suggested only in the case of two of the
isoforms identified in this study i.e., exon 2-6 and exon 6-7 (Table 1 and Table S3). We conclude that
the reverse complementary sequences of intronic Alu elements did not contribute to the back-splicing
events of circANRIL. As an example, exon 10-4 and exon 6-14 junctions do not fit the above category,
and alternative mechanisms need to be investigated. These results suggest that although some of the
circRNAs caused by back-splicing may be explained by presence of complementary Alu elements that
are in reverse orientation to one another and are situated on the 5′ and 3′ side of the back-splicing region,
many back-splicing events found here cannot be explained by these events and must be facilitated by
other unknown factors. Exon skipping has also been considered as a plausible mechanism of circular
RNA formation [19], but was not the case for circANRIL.
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3.4. Localisation of Circular and Linear ANRIL
LncRNAs must localise to their specific and diverse sites of action. Their location within cells
is an important clue to assigning function. For instance, finding a lncRNA primarily in the nucleus
near its site of transcription may suggest that it regulates transcription of a proximal gene (that is,
regulation in cis or regulation of proximal loci in three dimensions) [20]. We attempted to correlate
isoform heterogeneity with subcellular localisation, which might suggest hypotheses for potential
roles [21].
With respect to linear ANRIL, our results confirmed that both proximal and distal exons (exon
1, exon 13b and exon 19) are predominantly found in the nucleus (Figure 4B,C and Figure S6B–F).
However, a small proportion of the middle exons (exon 5, exon 6 and exon 7) is present in both nucleus
and cytoplasm (Figure 4B,C and Figure S6B–F). Nuclear enrichment of the linear isoforms indicates that
they may regulate transcription, possibly by association with PRC2 complexes as reported previously
(Figure 5) [7,8]. However, no association was found between PRC2 complexes and full length or
truncated ANRIL in urothelial carcinoma, and also possibly in melanoma [22]. Several other functions
for linear ANRIL have also been reported (Figure 5) [23,24], which leaves further scope for linear
ANRIL functions to be explored in melanoma.
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Figure 5. Functional overview of ANRIL and pathways. Schematic of pathways associated with ANRIL.
ANRIL is associated with proliferation and invasion by repression of p15, p16, p14, KLF2 and p21 via
PRC1 and PRC2 complexes [7,25]. ANRIL is induced by activation of the NF-κB pathway, and forms a
complex with transcription factor YY1 to exert transcriptional regulation on inflammatory genes IL6
and IL8 [23]. ANRIL is up-regulated by the transcription factor E2F1 in an ATM-dependent manner
following DNA damage, and elevated levels of ANRIL suppress the expression of CDKN2A/B at late
stages of the DNA damage response, allowing cells to return to normal at the completion of DNA
repair [24]. Green lines indicate induction and red lines indicate suppressio .
A major proportion of circANRIL was localised in the cytoplasm for most melanoma cell lines
(Figure 4D,E and Figure S7A–E). This suggests its involvement in post-transcriptional regulatory
mechanisms. Recently, circANRIL was found to disrupt exonuclease-mediated pre-rRNA processing
and ribosome biogenesis in vascular smooth muscle cells and macrophages by binding to pescadillo
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homologue 1 (PES1), an essential 60S preribosomal assembly factor [15]. Consequently, circANRIL
induced nucleolar stress and p53 activation resulting in induction of apoptosis and inhibition of the
cell cycle, which would be expected to confer protection against the development of atheroma, and
also tumour development [15]. However, cytoplasmic localisation of circANRIL in melanoma cell lines
suggests that expression of isoforms is tissue specific, implicating circANRIL in alternative functions.
Additionally, based on the heterogeneity of isoforms found in our preliminary study, we propose
that our cell lines possess divergent RNA processing activities. In uveal [26,27] and blue-nevus [28]
melanomas, mutations in the SF3B1 splicing factor arise recurrently; in carcinomas and gliomas,
the regulator SRPK1 is overexpressed [29]. These effects have not been reported for cutaneous
melanoma. It is possible that more subtle variations in splicing factor expression might underlie
isoform heterogeneity in melanoma cells. For example the lncRNA MALAT-1 has been associated
with splicing [30], binds to SRSF1, at least in kidney tissue [31], and is overexpressed in metastatic
melanoma [32,33]. The heterogeneity of processed lncRNAs, to which our study points, suggests the
hypothesis that one class of lncRNA may regulate isoform selection of another class of lncRNA with
splicing factors as intermediates. Characterisation of further lines would help clarify the processing
mechanisms involved.
Systematic work to catalogue ANRIL isoforms in multiple cell lines of the same and different
tumour types, including representatives of normal, noncancerous cells, will be needed. Future studies
will combine with this study to provide a picture of how the isoforms are produced in different tumour
cell lines. Only then will the function of “ANRIL” (or, more appropriately, the multiplicity of ANRIL)
be disclosed.
4. Materials and Methods
4.1. Culture Conditions of Melanoma Lines
The New Zealand melanoma (NZM) cell lines were generated from surgical samples of metastatic
melanoma as previously described [34]. Written consent was obtained from all patients under
Auckland Area Health Board Ethics committee guidelines. NZM cell lines were grown under low
oxygen conditions (5% O2) in order to mimic physiologically low oxygen levels in tumours. NZM cell
lines were grown in α-modified minimal essential medium (αMEM; Life Technologies, Carlsbad, CA,
USA) supplemented with insulin (5 µg/mL), transferrin (5 µg/mL) and sodium selenite (5 ng/mL;
Roche Applied Sciences, Penzberg, Germany), 100 U/mL of penicillin, 100 µg/mL of streptomycin
(PS) and 5% fetal bovine serum (FBS).
4.2. RNA Isolation and cDNA Synthesis
Total RNA from cultured cells or RNA from cell fractions was purified using Trizol (Life
Technologies, Carlsbad, CA, USA) and treated with DNase I (Sigma-Aldrich, St. Louis, MO, USA)
according to the manufacturer’s instructions. Random hexamers was used to make cDNA using 1 µg
of RNA with M-MLV-Reverse Transcriptase (Sigma-Aldrich) according to manufacturer’s instructions.
4.3. Reverse Transcription-PCR (RT-PCR)
PCR primers (Table S1) were designed using Primer3 v. 0.4.0 software (Whitehead Institute,
Cambridge, MA, USA). For non-quantitative expression analysis, PCR reactions were performed in a
final volume of 20 µL, containing 1X PCR buffer, cDNA at a final 1 in 10 dilution, 0.3 µM forward and
reverse primers each, 5 U Taq Polymerase, 0.2 mM deoxynucleoside triphosphates, and 2.5 mM MgCl2.
The cycling conditions used for NEAT1 and GAPDH were as follows: 95 ◦C for 10 min, 30 × 95 ◦C for
30 s, 60 ◦C for 45 s, and 72 ◦C for 1 min, and 72 ◦C for 15 min. Amplified products were visualized
after electrophoresis on a 0.5–1% agarose gel.
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4.4. Quantitative PCR (qPCR)
All primers (Integrated DNA Technologies, Coralville, IA, USA) used for qPCR were designed
using Primer3 v. 0.4.0 software. qPCR was performed with a final 1 in 10 dilution of cDNA, 0.8 µM
primers and 1x Sybr Green MasterMix (Life Technologies). Primer efficiencies were calculated using
the equation: Efficiency = 10−1/slope. For normalisation of transcript expression levels, 18S and 28S
ribosomal RNA (rRNA), or GAPDH and HPRT were used as reference transcripts. The average
expression of these reference genes was used to calculate the relative expression of the genes of interest.
4.5. Gene Expression and TCGA Data Analysis
The RNAseq and exon expression data from TCGA Skin Cutaneous Melanoma (SKCM) gene
expression (Illumina Hi-Seq) and exon expression (Illumina Hi-Seq) were used to examine the gene
expression and exon expression respectively. Statistical analysis was performed using Sigma-Plot.
Correlation analysis was performed with Pearsons Product Moment Correlation (R) and statistical
significance (p). To examine the exon expression, we derived the expression level of each exon based
on its chromosomal location and the average value for each exon used in bar graph (Figure 1B–D and
Figure S1A–C).
4.6. PCR and Sequencing of the Exon 14-5 Junction of circANRIL
For qPCR and RT-PCR of circANRIL, primers pointing in opposite directions on exon 14-5 were
designed, as described in [10], using Primer3 v. 0.4.0 software (Whitehead Institute, Cambridge, MA,
USA). RT-PCR reactions were performed as mentioned before. The cycling conditions for RT-PCR used
were as follows: 95 ◦C for 15 min, 35 × 94 ◦C for 30 s, 59 ◦C for 30 s, and 72 ◦C for 1 min, and 72 ◦C for
2 min. The correct sizes of the products were confirmed on 1% agarose gels. Excess primers in PCR
products were removed using a PureLink PCR Purification Kit (Life Technology, Waltham, MA, USA)
according to the manufacturer’s instructions. Concentrations of PCR products were determined using
a nanodrop spectrophotometer (ND-1000, NanoDrop, ThermoFisher Scientific, Rockford, IL, USA).
Sequencing was performed in two directions using ABI Prism 3730xl Genetic Analyzer with the ABI
PRISM Big Dye Terminator Cycle Sequencing Ready Reaction kit, version 3.1 (Applied Biosystems,
Foster City, CA, USA).
4.7. Stability Assay for Circular and Linear Isoforms of ANRIL
Melanoma cell lines NZM7 and NZM37 were treated with 10 µg/mL actinomycin D
(Sigma-Aldrich) for 2, 6, 8 and 12 h. Total RNA from the cells was isolated for each point and cDNA
synthesised as described before. Quantitative PCR was then done using primer sets for exon 1 and
the exon 14-5 junction indicative of the presence of linear and circular isoforms of ANRIL respectively,
relative to the expression of GAPDH. Linear regression analysis was performed to determine stability
for both NZM7 and NZM37.
4.8. Characterisation of circANRIL Isoform Using Outward Facing Primer
Outward facing primers were used against exons 2, 4, 6, 7, 8, 14 and 16 with forward primer against
the 3′ end of each exon and reverse primer against 5′ end of the same exons. RT-PCR conditions used
were the same as mentioned before. When multiple bands were detected, cloning of the PCR products
was conducted using a pGEM®-T Vector cloning kit (Promega, Madison, WI, USA). Sequencing of the
resulting clones using T7 and SP6 primers was performed in two directions using ABI Prism 3730xl
Genetic Analyzer as above.
4.9. Intron and Exon Repeat Elements Analysis
For the Alu elements enrichment analysis we extracted the DNA repetitive Alu elements from the
rmsk table for human genome (hg19) downloaded from University of California, Santa Cruz (UCSC)
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genome browser. We also extracted the circRNA genomic regions from circBase [35]. We used the
UCSC genes annotations in our analysis. All the analysis was performed in R [36] version 3.3.2. For the
Pearson Chi-squared test and the correlation tests the relevant function in stats package of R was
used. The pairwise alignment function in the Biostrings [36] package of R used to distinguish the Alu
elements that are reverse compliment of one another (a minimum alignment score threshold of −200
was used). Jonckheere Terpstra test provided by the clinfun [37] R package was used to test whether
there are ordered differences among values in 2 classes.
4.10. Exon Skipping Alternative Splicing Analysis
We extracted all the known Exon skipping from the RefSeq database using generate Events feature
of SUPPA [37]. Next, we extracted all sets of exons of ANRIL that are positioned within these exon
skipping events, i.e., the potential exons to form circANRIL isoforms. Eventually, we compared the
potential list to our discovered circANRIL isoforms.
4.11. Cell Fractionation
The Lamond lab protocol was used for cell fractionation, as described in http://www.lamondlab.
com/pdf/CellFractionation.pdf. Cultured melanoma cells, around 80–90% confluent, were trypsinised
and pelleted. The cells were placed in hypotonic buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT) for 5 min. Cells were lysed using a Wheaton Dounce tissue homogeniser
(Fisher Scientific, Waltham, MA, USA). Lysed cells were then centrifuged at 1000 rpm at 4 ◦C for 5 min
and the supernatant was collected as the cytoplasmic fraction and RNA from cytoplasmic fractions
was isolated using Trizol (Life Technology) as described above. The cell pellet was applied to a sucrose
cushion followed by centrifugation at 600× g for 15 min. The supernatant was discarded and the pellet
was stored as the nuclear fraction and nuclear RNA was isolated using Trizol (Life Technology) as
described above. The purity of the cell fractions was examined by RT-PCR using NEAT1 as a nuclear
marker, and the quality of RNA obtained from each fraction was assessed using GAPDH. qPCR was
done for the cell fractions using different primer sets for linear and circANRIL isoforms.
5. Conclusions
In this study we investigated the differential expression of ANRIL isoforms in melanoma cell lines.
The results led us to the discovery of multiple linear and circular ANRIL species. We also characterized
the different isoform of circANRIL in these cell lines and revealed the presence of an assortment of
circular isoforms with varying lengths, exon-exon junctions and exon combinations. By analysing the
length of introns and presence of Alu elements in introns, we found that formation of non-canonical
back-spliced junctions was not mainly determined by these factors. We also observed that linear and
circANRIL isoforms differ in their subcellular localisation, with linear isoforms enriched in the nucleus
and circANRIL enriched in the cytoplasm. Based on our findings on subcellular localization of linear
and circular ANRIL and lack of correlation between their expression, we hypothesise that “ANRIL”
has wholly distinct dual sets of functions in melanoma cell lines. This reveals the dynamic nature of
the locus and constitutes a basis for investigating the functions of ANRIL in melanoma.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/7/1378/s1.
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